ArticleInternational journal of hematology2025
Successful treatment of myeloid blast phase chronic myelogenous leukemia with the JAK2 V617 F mutation by combination therapy with asciminib and ropeginterferon alfa-2b in an elderly patient.
Satoko Oka et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.